PDEF is a negative regulator of colon cancer cell growth and migration
- 14 October 2009
- journal article
- research article
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 108 (6), 1389-1398
- https://doi.org/10.1002/jcb.22371
Abstract
ETS is a family of transcriptional regulators with functions in most biological processes. Dysregulated ETS factor function leads to altered expression of multiple genes that play critical roles in many of the processes required for cancer progression. While the Ets family gene, p rostate‐d erived E TS f actor (PDEF), is expressed in epithelial tissues including prostate, breast, and colon, PDEF protein expression has been found to be reduced or lost during prostate and breast cancer progression. The goal of this study was to examine the expression and biologic impact of altered PDEF expression in colon cancer. PDEF mRNA and protein are not detectable in several colon‐cancer‐derived cell lines. Re‐expression of PDEF in colon cancer cells inhibits growth and migration. Growth affects are due to altered cellular proliferation, indicated by increased altered cell population in G1 and S phases of the cell cycle, as well as increased apoptosis. Relevant to its modulation of growth and migration phenotypes, PDEF expression resulted in altered expression of genes with established roles in cell cycle, motility, and invasion. Furthermore, chromatin immunoprecipitation studies show that p21 and urokinase plasminogen activator (uPA) are direct PDEF transcriptional targets. While non‐tumor colon epithelium expresses PDEF mRNA and protein, the majority of tumors showed decreased mRNA and/or protein expression. In human tumor tissue samples, PDEF expression was inversely correlated with the expression levels of uPA. Collectively, the data support the model that PDEF is a negative regulator of tumor progression by modulating the expression of growth and migration promoting genes. J. Cell. Biochem. 108: 1389–1398, 2009.Keywords
This publication has 36 references indexed in Scilit:
- ETS transcription factors: oncogenes and tumor suppressor genes as therapeutic targets for prostate cancerExpert Review of Anticancer Therapy, 2008
- A urokinase‐type plasminogen activator deficiency diminishes the frequency of intestinal adenomas in ApcMin/+ miceThe Journal of Pathology, 2007
- Defining ETS transcription regulatory networks and their contribution to breast cancer progressionJournal of Cellular Biochemistry, 2007
- Reduced PDEF Expression Increases Invasion and Expression of Mesenchymal Genes in Prostate Cancer CellsCancer Research, 2007
- Prostate-Derived ETS Factor Is a Mediator of Metastatic Potential through the Inhibition of Migration and Invasion in Breast CancerCancer Research, 2007
- The Morphogenetic Code and Colon Cancer DevelopmentCancer Cell, 2007
- Matrix metalloproteinase-7-catalyzed release of HB-EGF mediates deoxycholyltaurine-induced proliferation of a human colon cancer cell lineBiochemical Pharmacology, 2006
- Prostate-derived Ets transcription factor (PDEF) downregulates survivin expression and inhibits breast cancer cell growth in vitro and xenograft tumor formation in vivoBreast Cancer Research and Treatment, 2006
- ETS transcription factors and their emerging roles in human cancerEuropean Journal Of Cancer, 2005
- Matrix metalloproteinase-7 degrades all insulin-like growth factor binding proteins and facilitates insulin-like growth factor bioavailabilityBiochemical and Biophysical Research Communications, 2005